Credit Suisse Ag Erasca, Inc. Transaction History

Credit Suisse Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$1.67 - $2.49 $12,234 - $18,241	7,326 Added 17.42%	49,371 $105,000
Q3 2023 Nov 13, 2023	SELL	$1.97 - $2.91 $4,832 - $7,138	-2,453 Reduced 5.51%	42,045 $82,000
Q2 2023 Aug 11, 2023	SELL	$2.57 - $3.3 $89,754 - $115,249	-34,924 Reduced 43.97%	44,498 $122,000
Q1 2023 May 10, 2023	BUY	$2.74 - $4.44 $29,008 - $47,006	10,587 Added 15.38%	79,422 $239,000
Q4 2022 Feb 13, 2023	BUY	$3.89 - $8.57 $194,169 - $427,771	49,915 Added 263.82%	68,835 $296,000
Q3 2022 Nov 10, 2022	BUY	$5.82 - $10.68 $1,792 - $3,289	308 Added 1.65%	18,920 $148,000
Q2 2022 Aug 12, 2022	BUY	$4.58 - $8.72 $2,954 - $5,624	645 Added 3.59%	18,612 $103,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $20,012 - $36,021	2,327 Added 14.88%	17,967 $154,000
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $195,656 - $355,810	15,640 New	15,640 $243,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $311M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.